Flavia Pichiorri, Ph.D., M.S. is an experienced professor in the Department of Hematologic Malignancies Translational Science, Judy and Bernard Briskin Center for Multiple Myeloma Research, Beckman Research Institute of The City of Hope and the Translational Scientist Leader for the institution’s Multiple Myeloma Disease Team. Flavia received her MS from the University of Rome “Tor Vergata” where she graduated the US equivalent of Summa Cum Laude and was awarded a Fellowship at the University of Rome and Italian National Council of Research. In 2006, Flavia received her Ph.D. in Experimental Medicine from the University of Rome “Tor Vergata”.

Over the course of Flavia Pichorri’s career, she has remained incredibly active within her field, contributing to more than 100 peer-reviewed publications and 29 published abstracts. Notably, Flavia’s work as a postdoctoral fellow and research fellow is underlined by the study of fragile genomic sites in cancer and epigenetic and small RNA deregulation findings furthering myeloma research. At Pichiorri Lab, Flavia leads a team of talented scientists who leverage state-of-the-art technologies and research with the goal of improving healthcare outcomes for cancer patients. Pichiorri Lab is currently conducting clinical trials in areas such as drug repurposing, maintenance approaches, amyloidosis, and oncolytic viruses.

Flavia Pichiorri is recognized within her field for the contributions that she has made to myeloma research, including demonstrating that small RNA and epigenetic changes play a role in the malignant transformation of plasma cells, that many of these changes can be reverted using small molecular inhibitors, developing, detecting, and treating myeloma cell dissemination with anti-CD38 antibodies conjugate with radiotracer or therapeutic isotope in both preclinical and clinical studies. Her team recently developed a novel single chain CD38 T cell engager able to reactivate the immune suppressive cancer immune environment for the treatment of both leukemia and multiple myeloma patients. Colleagues and collaborators note that Flavia is a scientist who holds extensive knowledge in her areas such as hematologic malignancies and myeloma research and remains committed to develop, test, and translate into the clinic the next generation of immune multiple myeloma and leukemia treatments to improve health outcomes for a disease currently incurable for many patients. Her laboratory also focuses on understanding mechanisms of resistance to current immune and cellular based therapies in multiple myeloma by using single cell mass cytometry analysis to analyze the immune system of each patient to early predict response and/or acquired mechanisms of resistance. In collaboration with her colleagues in the department of computational quantitative medicine she developed an immune algorithm that has the potential to drive specific therapeutic interventions in function of the immune system of each patient.

Interested in More form Flavia Pichiorri?

FlaviaPichiorri.com is a platform for learning more about Dr. Pichiorri’s research as well as recent scientific developments linked to her field. Below are a few types of areas that future content on this site will explore to the benefit of interested readers.

Flavia Pichiorri’s Research

The primary goal of this site is to further explore the research of Dr. Pichiorri by providing high-level information on some of her most prolific work. Content covering Flavia Pichiorri’s research will include insights on:

• CD38 Targeting Therapy in Multi-Relapsing Myeloma Patients: Dr. Pichiorri and her team at City of Hope have been heavily involved in myeloma research, with two clinical trials studying CD38. With this in mind, readers can expect that future posts will address both the team’s CD38 comparison study and Daratumumab’s effects on CD38 and myeloma cell adhesion. Through further exploring this research, Flavia Pichiorri hopes to help readers develop a clearer understanding of the work conducted by her team as well as how findings are contributing to crucial conversations linked to myeloma research.
• Using Oncolytic Viruses in Myeloma: Dr. Pichiorri has been involved in studies utilizing oncolytic viruses to further myeloma research. A few of these studies include A Phase 1 Trial of Single Agent Reolysin in Patients with Relapsed Multiple Myeloma, Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo, and Reolysin-based combination therapy in relapsed multiple myeloma. Dr. Pichiorri finds that research using oncolytic viruses can provide insights crucial for the development of effective therapeutic strategies for multiple myeloma. To this end, information on her research can be valuable as teams work toward the unified goal of curing the second most common hematologic cancer.
• Additional Research Conducted by Dr. Pichiorri: In addition to her studies linked to CD38 targeting therapy in multi-relapsing myeloma patients and using oncolytic viruses in myeloma, Dr. Flavia Pichiorri has conducted a wide range of research over the course of her career. If you are interested in learning more about Flavia’s other contributions to myeloma and leukemia research and the impact of these studies, this site has you covered. Content inspired by Flavia Pichiorri’s research will also include information on ongoing clinical trials led by her teams as well as publications and abstracts that she has been a part of since the start of her career.

Professional Insights

Dr. Flavia Pichiorri’s time as a scientist and researcher have led to her developing a wide range of specialties and insights that can be beneficial to those who are currently pursuing successful careers within the industry. Dr. Pichiorri acknowledges that now, more than ever, scientists are looking for ways to hone their skills and learn from experienced leaders interested in contributing to the next generation of talent. For this reason, future professional development content aims to draw from Flavia’s experiences to share insight empowering scientists to seize additional learning opportunities, remain motivated and committed to conducting high-level research, and adapt to challenges as they continue the path to successful careers.

Recent Scientific Developments

While this site primarily will cover information linked to Dr. Pichiorri’s research, she realizes that her field and adjacent areas of study are constantly in a state of development that leads the way to new findings, advancements, and innovations for the sake of patients. Readers can expect that content on this site will address recent scientific developments currently playing a pivotal role in myeloma and cancer research as well as information on the scope and impact of these findings. Through insights on recent news related to her areas of expertise, Dr. Flavia hopes to shine a light on interesting changes that, along with her research, may bring improved healthcare outcomes to cancer patients.

Interested in learning more about myeloma research, Dr. Flavia’s work, scientific developments, and a variety of associated topics from Flavia Pichiorri? Tune in to this site frequently for more informative content inspired by Dr. Pichiorri’s insights.